CeriBell, Inc.

NASDAQ:CBLL

Medical - Devices

Healthcare
$25.63 +1.42%

+$0.25 today

Market cap
$995.34M
Beta
0.84
P/E (TTM)
-10.9
EPS (TTM)
-$1.60
52W Low $10.85High $24.33

Volume 0.41M

Average 0.29M

CBLL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

CeriBell, Inc.NASDAQ: CBLL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $23.12M rose 28.4% year over year, behind the +34.5% change in trailing-twelve-month gross profit. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Gross profit amounted to 87.9% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.4% toward the trailing-twelve-month pace of +34.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.12M+6.8% QoQ
Last fiscal yearDec 2025
$78.27M+37.9% YoY
LTMMar 2026
$83.39M+34.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.4%——
1 year+37.9%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
78.27M USD
Year-over-year change
+37.9%
3-year CAGR
+53.9%

Gross Profit vs competitors

How CBLL compares with its peers on the latest reported figures

  • CBLL's LTM Mar 2026 gross profit of $83.39M is the 2nd highest of the 7 companies compared; the peer median is $61.62M.
  • Its year-over-year change of +34.5% is the 2nd highest of 7, against a peer median of +25.8%.
  • Gross profit amounts to 87.7% of revenue for CBLL, versus a peer median of 76.9%.
CBLL Competitors Peer median
Gross Profit for CBLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LIVNLivaNova PLCLTM Sep 2026$1.02B +10.7%+9.9%67.9%
CBLLCeriBell, Inc.LTM Mar 2026$83.39M +34.5%+53.9%87.7%
NPCENeuroPace, Inc.LTM Mar 2026$77.93M +23.5%+33.4%78.3%
STIMNeuronetics, Inc.LTM Mar 2026$72.72M +28.0%+13.3%48.0%
CVRXCVRx, Inc.LTM Mar 2026$50.52M +14.2%+40.4%85.5%
BWAYBrainsWay Ltd.LTM Mar 2026$42.45M +31.1%+25.2%75.5%
ECORelectroCore, Inc.LTM Mar 2026$30.45M +35.0%+58.5%87.2%
Peer median (excluding CBLL) $61.62M+25.8%+29.3%76.9%

Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.92M45.23M65.44M89.06M
Cost of Revenue4.43M7.06M8.69M10.79M
Gross Profit21.49M38.16M56.75M78.27M
Gross Margin82.9%84.4%86.7%87.9%
Research & Development7.24M9M13.56M19.14M
Selling, General & Admin50.27M59.21M82.9M117.53M
Operating Expenses57.51M68.2M96.46M136.68M
Depreciation & Amortization497K847K1.14M1.34M
EBITDA(35.06M)(26.51M)(37.32M)(50.18M)
EBITDA Margin-135.3%-58.6%-57.0%-56.3%
Operating Income(36.02M)(30.04M)(39.71M)(58.4M)
Operating Margin-139.0%-66.4%-60.7%-65.6%
Interest Income0000
Interest Expense1.6M2.1M1.99M1.89M
Other Income / Expenses(1.14M)588K(746K)4.99M
Income Before Tax(37.16M)(29.45M)(40.46M)(53.41M)
Pre-Tax Margin-143.4%-65.1%-61.8%-60.0%
Income Tax Expense2K11K00
Net Income(37.16M)(29.46M)(40.46M)(53.41M)
Net Margin-143.4%-65.1%-61.8%-60.0%
EPS (Basic)(1.59)(1.26)(3.39)(1.46)
EPS (Diluted)(1.59)(1.26)(3.39)(1.46)
Weighted Avg Shares23.32M23.32M11.95M36.54M
Weighted Avg Shares (Diluted)23.32M23.32M11.95M36.54M

CeriBell, Inc.

NASDAQ:CBLL

Intrinsic Alpha fair value

Locked

Current Price

$25.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.